Pulmonary & Nasal Drug Delivery72

Issue No #72 December 1st, 2016

Issue 72 - Nov 16

Inside the magazine

SELECTION OF EXCIPIENTS FOR DRY POWDER INHALERS

SELECTION OF EXCIPIENTS FOR DRY POWDER INHALERS

Harry Peters and Gerald Hebbink explain how, because dry powder inhalers need a carrier to help with ensuring the drug is effectively delivered, interest has been focused on developing inhalation-grade lactose for this purpose.

LEVERAGE TECH TO OVERCOME PULMONARY DELIVERY BARRIERS

Jean Vuillecard

LEVERAGE TECH TO OVERCOME PULMONARY DELIVERY BARRIERS

Jean Vuillecard and Eric Dessertenne define the limitations of traditional strategies to train, educate and track adherence with inhaled therapeutics and show how connectivity and other add-on digital tech can support these strategies healthcare providers require.

PATIENT PREFERENCE: DEVICE TRAINING & EDUCATION TOOLS

PATIENT PREFERENCE: DEVICE TRAINING & EDUCATION TOOLS

Paul Sullivan and Craig Baker point out that most patients with asthma do not use their inhaler properly, and review evidence from a trial of five different methods designed to improve inhaler use. They conclude that training devices could be effective tools to increase patient confidence and reduce anxiety.

AN ENVIRONMENTALLY FRIENDLY & EFFICIENT DOSAGE FORM

Susana Ecenarro

AN ENVIRONMENTALLY FRIENDLY & EFFICIENT DOSAGE FORM

Susana Ecenarro Probst presents evidence, set against the backdrop of environmental concerns over HFC propellants in MDIs, supporting the adoption of dry-powder inhalers as an attractive alternative.

LEARNING TO WALK BEFORE WE RUN

LEARNING TO WALK BEFORE WE RUN

David Harris highlights basic problems with inhalers that persist today, and describes why - as the industry looks increasingly towards developing "smart" and connected inhalers - it is important to remember to solve these basic problems.

SCALING-UP FOR HIGH DOSE DELIVERY TO THE LUNGS

Dr João Ventura Fernandes

SCALING-UP FOR HIGH DOSE DELIVERY TO THE LUNGS

João Ventura Fernandes, Gonçalo Rebelo de Andrade and Peter Villax describe the scaling up of the currently marketed TwinCaps® inhaler into the new TwinMax™ design for high-dose delivery of challenging drug-alone formulations in single to short-term treatments and emergency situations.

GENERIC NEBULISER BIOEQUIVALENCE: OPTIMISING ANALYTICAL STRATEGIES

Déborah Le Pennec

Malvern Panalytical

GENERIC NEBULISER BIOEQUIVALENCE: OPTIMISING ANALYTICAL STRATEGIES

Déborah Le Pennec, Laurent Vecellio, Paul Kippax and Stephane Rouquette look at the optimal application of laser diffraction and automated imaging within the context of the US FDA guidance for the in vitro demonstration of bioequivalence in a generic nebuliser.

A TRUE PLATFORM OFFERING EFFICIENT NASAL DOSE DELIVERY

A TRUE PLATFORM OFFERING EFFICIENT NASAL DOSE DELIVERY

Millions of people suffering from allergic rhinitis use nasal sprays manufactured by Nemera every day. Pascale Farjas, provides an overview of an innovative nasal delivery system, Advancia®, a true platform.

Top